Genome editing in Rhizopus delemar using using CRISPR-Cas systems

使用 CRISPR-Cas 系统对德勒马根霉进行基因组编辑

基本信息

  • 批准号:
    9304959
  • 负责人:
  • 金额:
    $ 18.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

Zygomycosis is the third most common invasive fungal infection that causes devastating diseases in individuals with immune deficiency, such as those with neutropenia or diabetic ketoacidosis. Mortality due to zygomycosis is very high, with a nearly 50% fatality rate even when appropriately treated. Due to the increasing prevalence of diabetic ketoacidosis, cancer, and organ transplantation, the number of patients at risk is dramatically increasing, such as in the case of a recent outbreak of hospital acquired Rhizopus delemar infection in New Orleans, which resulted in the death of at least six children. Despite such importance, very limited research resources are available to investigate R. delemar pathogenesis. This is partially due to the organism being not as genetically tractable as other pathogenic fungi. For example, there often exist multiple gene copies due to whole-genome duplication, and few mitotically stable genetic transformants can be obtained with the existing methodology. We propose to develop a CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated) system that allows efficient gene specific manipulation and custom genome editing in R. delemar. We will begin by characterizing unique clinical strains in comparison to the archetypical strain for characteristics relevant to pathogenicity, auxotrophy, and resistance to antifungal compounds. We will construct vectors for Cas9 nuclease and guide RNA (gRNA) expression using the endogenous promoter and terminator sequences. We will then test the utility of the CRISPR-Cas system through manipulation of the marker PYRF (URA5) gene encoding orotidine phosphate decarboxylase, and the CNBR and CNA(A-C) genes encoding regulatory and catalytic subunits of calcineurin whose homologs play critical roles in fungal growth, morphogenesis, drug resistance, and pathogenesis. Successful implementation of our research plan will provide a revolutionary tool in promoting genetic studies of R. delemar pathogenesis mechanism.
接合菌病是第三种最常见的侵袭性真菌感染, 具有免疫缺陷的个体,例如具有中性粒细胞减少症或糖尿病酮症酸中毒的个体。死亡率 真菌病的发病率非常高,即使经过适当治疗,死亡率也接近50%。由于 糖尿病酮症酸中毒、癌症和器官移植的患病率增加, 风险急剧增加,例如最近医院获得性根霉病爆发的情况 新奥尔良的delemar感染导致至少6名儿童死亡。尽管有这样 重要的是,非常有限的研究资源可用于研究R。delemar发病机制。这是 部分原因是该生物体不像其他致病真菌那样易于遗传。比如说, 由于全基因组复制,通常存在多个基因拷贝,很少有有丝分裂稳定的遗传 可以用现有的方法获得转化体。我们建议开发CRISPR-Cas (重复的规则间隔短回文重复序列-CRISPR相关)系统, 高效的基因特异性操作和定制的基因组编辑。delemar。我们将开始 与原型菌株相比,表征独特临床菌株的相关特征, 致病性、营养缺陷型和抗真菌化合物抗性。我们将构建Cas9的载体, 使用内源启动子和终止子序列的核酸酶和指导RNA(gRNA)表达。 然后,我们将通过操纵标记PYRF(URA 5)来测试CRISPR-Cas系统的效用。 编码乳清酸核苷磷酸脱羧酶的基因,以及编码 钙调神经磷酸酶的调节和催化亚基,其同系物在真菌生长中起关键作用, 形态发生、耐药性和发病机制。我们的研究计划的成功实施将 为R. delemar发病机制。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Heat-Shock Proteins MoSsb1, MoSsz1, and MoZuo1 Attenuate MoMkk1-Mediated Cell-Wall Integrity Signaling and Are Important for Growth and Pathogenicity of Magnaporthe oryzae.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PING WANG其他文献

PING WANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PING WANG', 18)}}的其他基金

Towards a genome-wide CRISPR/Cas9 mutant library in Rhizopus delemar
德莱马根霉 (Rhizopus delemar) 中的全基因组 CRISPR/Cas9 突变体文库
  • 批准号:
    10573271
  • 财政年份:
    2022
  • 资助金额:
    $ 18.25万
  • 项目类别:
Towards a genome-wide CRISPR/Cas9 mutant library in Rhizopus delemar
德莱马根霉 (Rhizopus delemar) 中的全基因组 CRISPR/Cas9 突变体文库
  • 批准号:
    10431481
  • 财政年份:
    2022
  • 资助金额:
    $ 18.25万
  • 项目类别:
Isolation of mononuclear propagules from coenocytic hyphae of the mucormycosis pathogen Rhizopus delemar
从毛霉菌病病原体德莱马根霉的共生菌丝中分离单核繁殖体
  • 批准号:
    10353429
  • 财政年份:
    2021
  • 资助金额:
    $ 18.25万
  • 项目类别:
Isolation of mononuclear propagules from coenocytic hyphae of the mucormycosis pathogen Rhizopus delemar
从毛霉菌病病原体德莱马根霉的共生菌丝中分离单核繁殖体
  • 批准号:
    10221180
  • 财政年份:
    2021
  • 资助金额:
    $ 18.25万
  • 项目类别:
RADX TECH PROJECT - WORK PACKAGE 1 SUPPORT
RADX 技术项目 - 工作包 1 支持
  • 批准号:
    10505995
  • 财政年份:
    2021
  • 资助金额:
    $ 18.25万
  • 项目类别:
Mechanisms of Radiation-induced Vascular Endothelial Cell Injury and Its Correction
辐射引起的血管内皮细胞损伤的机制及其纠正
  • 批准号:
    9391119
  • 财政年份:
    2017
  • 资助金额:
    $ 18.25万
  • 项目类别:
Genome editing in Rhizopus delemar using using CRISPR-Cas systems
使用 CRISPR-Cas 系统对德勒马根霉进行基因组编辑
  • 批准号:
    9179413
  • 财政年份:
    2016
  • 资助金额:
    $ 18.25万
  • 项目类别:
Novel Approaches to Maintaining Organ Function in Sepsis
维持脓毒症器官功能的新方法
  • 批准号:
    10405950
  • 财政年份:
    2016
  • 资助金额:
    $ 18.25万
  • 项目类别:
Novel Approaches to Maintaining Organ Function in Sepsis
维持脓毒症器官功能的新方法
  • 批准号:
    10153818
  • 财政年份:
    2016
  • 资助金额:
    $ 18.25万
  • 项目类别:
Novel Approaches to Maintaining Organ Function in Sepsis
维持脓毒症器官功能的新方法
  • 批准号:
    9698963
  • 财政年份:
    2016
  • 资助金额:
    $ 18.25万
  • 项目类别:

相似海外基金

Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
  • 批准号:
    MR/Y002164/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Research Grant
Engineering microbial cell factories for production of improved polyene antifungal agents
工程微生物细胞工厂用于生产改进的多烯抗真菌剂
  • 批准号:
    2898887
  • 财政年份:
    2023
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Studentship
Morphological profiling for the development of antifungal agents
用于开发抗真菌药物的形态分析
  • 批准号:
    22H02216
  • 财政年份:
    2022
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
An efficient approach to find therapeutically effective antifungal agents
寻找治疗有效的抗真菌药物的有效方法
  • 批准号:
    22K05337
  • 财政年份:
    2022
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating light-activated therapeutic compounds as antifungal agents.
研究光激活治疗化合物作为抗真菌剂。
  • 批准号:
    2753345
  • 财政年份:
    2022
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Studentship
Discovery of novel therapeutic agents for biliary tract and pancreatic cancer based on antifungal agents
基于抗真菌药物的胆道癌和胰腺癌新型治疗药物的发现
  • 批准号:
    20H03533
  • 财政年份:
    2020
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of antifungal agents that target essential protein kinases in A. fumigatus.
开发针对烟曲霉必需蛋白激酶的抗真菌剂。
  • 批准号:
    2456629
  • 财政年份:
    2020
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Studentship
Development of Broad Spectrum Antifungal Agents
广谱抗真菌药物的开发
  • 批准号:
    9909111
  • 财政年份:
    2020
  • 资助金额:
    $ 18.25万
  • 项目类别:
Elucidation of tip growth factor of fungi and construction of screeing system for antifungal agents
真菌尖端生长因子的阐明及抗真菌药物筛选体系的构建
  • 批准号:
    19K05738
  • 财政年份:
    2019
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ambruticins: An inspiration to develop novel biocatalysts and antifungal agents
Ambruticins:开发新型生物催化剂和抗真菌剂的灵感
  • 批准号:
    2107517
  • 财政年份:
    2018
  • 资助金额:
    $ 18.25万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了